Table 1. Clinicopathological characteristics of patients.
Mayo Clinic | mFOLFOX6/XELOX | ||
---|---|---|---|
Characteristic | (n=95; n/%) | (n=160; n/%) | P-value |
Gender |
|
|
0.34 |
Male | 50/52.6 | 94/58.8 | |
Female |
45/47.4 |
66/41.2 |
|
Age (years) |
|
|
0.18 |
Median | 56.1 | 53.9 | |
Range |
27–78 |
26–83 |
|
Pathology |
|
|
0.31 |
G2 | 72/75.8 | 116/72.5 | |
G1 | 5/5.3 | 20/12.5 | 0.31 |
G3 |
18/19.1 |
24/15 |
|
Stage |
|
|
0.12 |
IIIA | 64/67.3 | 97/60.6 | |
IIIB | 24/25.3 | 53/33.1 | |
IIIC |
7/7.4 |
10/6.3 |
|
CEA |
|
|
0.76 |
<5 ng ml−1 | 63/66.3 | 108/67.5 | |
>5 ng ml−1 |
32/33.7 |
52/32.5 |
|
ERCC1 |
|
|
0.66 |
Positive | 52/54.7 | 88/55 | |
Negative |
43/45.3 |
72/45 |
0.66 |
MMR |
|
|
0.53 |
pMMR | 81/85.2 | 133/83.1 | |
dMMR |
14/14.8 |
27/16.9 |
|
Metastasis |
|
|
0.08 |
Yes | 45/47.4 | 64/40 | |
No |
50/52.6 |
96/60 |
|
Live |
|
|
0.02 |
Yes | 50/52.6 | 106/66.5 | |
No | 45/47.4 | 54/33.8 |
Abbreviations: CEA=carcinoembryonic antigen; dMMR=deficient MMR; ERCC1=excision repair cross-complementation group 1; MMR=mismatch repair; pMMR=proficient MMR.P-value of the chi-square test comparing characteristics distribution between the Mayo clinic group and mFOLFOX6/XELOX group. Metastasis means the postoperative metastasis.